


Vertebral fractures up with long-term delay of denosumab

July 28 2020



(HealthDay)—Compared with on-time dosing, delay of denosumab by

more than 16 weeks is associated with an increased risk for vertebral fractures, according to a study published online July 28 in the *Annals of Internal Medicine*.

Houchen Lyu, M.D., Ph.D., from the General Hospital of Chinese PLA in Beijing, and colleagues estimated the risk for fracture among denosumab users who delayed subsequent doses compared with those who received doses on time in a population-based cohort study. Data were included for 2,594 patients aged 45 years or older who initiated denosumab therapy for osteoporosis.

The researchers found that during six months, the risk for composite fracture was 27.3, 32.2, and 42.4 in 1,000 for on-time dosing, short delay (four to 16 weeks), and long delay (more than 16 weeks), respectively. For composite fracture, the hazard ratios for short and long delay were 1.03 (95 percent confidence interval, 0.63 to 1.69) and 1.44 (95 percent confidence interval, 0.96 to 2.17; P for trend = 0.093) compared with on-time injections. For [vertebral fractures](#), the hazard ratios were 1.48 (95 percent confidence interval, 0.58 to 3.79) and 3.91 (95 percent confidence interval, 1.62 to 9.45) for short and long delay, respectively.

"Because [patients](#) who used denosumab were at high risk for vertebral fracture, strategies to improve timely administration of denosumab in routine clinical settings are needed," the authors write.

More information: [Abstract/Full Text \(subscription or payment may be required\)](#)

Copyright © 2020 [HealthDay](#). All rights reserved.

Citation: Vertebral fractures up with long-term delay of denosumab (2020, July 28) retrieved 23

April 2024 from

<https://medicalxpress.com/news/2020-07-vertebral-fractures-long-term-denosumab.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.